180 Life Sciences Corp.
| NASDAQ: ATNF | Healthcare / Biotechnology / USA |
| 0.5708 | -0.0241 | -4.05% | Vol 36.33K | 1Y Perf -16.21% |
| Sep 22nd, 2023 15:58 DELAYED |
| BID | 0.5625 | ASK | 0.5900 | ||
| Open | 0.6192 | Previous Close | 0.5949 | ||
| Pre-Market | - | After-Market | 0.59 | ||
| - - | 0.02 2.91% |
| Target Price | 80.00 | Analyst Rating | — 0.00 | |
| Potential % | 13.92K | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/100 | Value Ranking | — - | |
| Insiders Value % 3/6/12 mo. | -/-/100 | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/100 | Income Ranking | — - | |
| Price Range Ratio 52W % | 5.87 | Earnings Rating | — | |
| Market Cap | 3.04M | Earnings Date | 9th Nov 2023 | |
| Alpha | 0.09 | Standard Deviation | 0.95 | |
| Beta | -2.47 |
Today's Price Range 0.56000.6338 | 52W Range 0.16067.15 |
Summary:
Sell
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -31.00% | ||
| 1 Month | -7.79% | ||
| 3 Months | -49.93% | ||
| 6 Months | -70.27% | ||
| 1 Year | -16.21% | ||
| 3 Years | -94.81% | ||
| 5 Years | - | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | - | |||
ROE last 12 Months | -50.45 | |||
ROA (5Y Avg) | - | |||
ROA last 12 Months | -32.09 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | -49.67 | |||
Return on invested Capital Q | -61.16 | |||
Return on invested Capital Y | -53.46 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 0.00 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -0.70 | ||||
| 0.76 | ||||
| - | ||||
| - | ||||
| -2.10 | ||||
| -8.05 | ||||
| -11.28 | ||||
| 6.98 | ||||
| 16.55M | ||||
| Forward PE | - | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 1.30 | ||||
| 1.40 | ||||
| 0.00 | ||||
| 0.02 | ||||
| -449.50 | ||||
| Leverage Ratio | 1.30 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.00 | ||||
| 0.00 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q01 2024 | - | -0.70 | - |
| Q03 2022 | - | -0.07 | - |
| Q02 2022 | - | 0.09 | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Next Report Date | 9th Nov 2023 |
| Estimated EPS Next Report | - |
| Estimates Count | - |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 36.33K |
| Shares Outstanding | 5.32K |
| Shares Float | 5.00M |
| Trades Count | 227 |
| Dollar Volume | 21.12K |
| Avg. Volume | 256.26K |
| Avg. Weekly Volume | 287.36K |
| Avg. Monthly Volume | 159.53K |
| Avg. Quarterly Volume | 321.88K |
180 Life Sciences Corp. (NASDAQ: ATNF) stock closed at 0.5708 per share at the end of the most recent trading day (a -4.05% change compared to the prior day closing price) with a volume of 36.33K shares and market capitalization of 3.03M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 0 people. 180 Life Sciences Corp. CEO is James N. Woody.
The one-year performance of 180 Life Sciences Corp. stock is -16.21%, while year-to-date (YTD) performance is -83.16%. ATNF stock has a five-year performance of %. Its 52-week range is between 0.16061 and 7.1499, which gives ATNF stock a 52-week price range ratio of 5.87%
180 Life Sciences Corp. currently has a PE ratio of -0.70, a price-to-book (PB) ratio of 0.76, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -32.09%, a ROC of -49.67% and a ROE of -50.45%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from 180 Life Sciences Corp., there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. 180 Life Sciences Corp.’s next earnings report date is 09th Nov 2023.
The consensus rating of Wall Street analysts for 180 Life Sciences Corp. is — (0), with a target price of $80, which is +13 915.40% compared to the current price. The earnings rating for 180 Life Sciences Corp. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
180 Life Sciences Corp. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
180 Life Sciences Corp. has a Sell technical analysis rating based on Technical Indicators (ADX : 19.51, ATR14 : 0.09, CCI20 : -41.27, Chaikin Money Flow : 0.13, MACD : -0.03, Money Flow Index : 62.86, ROC : -9.71, RSI : 43.15, STOCH (14,3) : 19.01, STOCH RSI : 0.23, UO : 51.84, Williams %R : -80.99), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of 180 Life Sciences Corp. in the last 12-months were: Pamir Ozan (Buy at a value of $5 214), Steinman Lawrence (Buy at a value of $22 140), Woody James (Buy at a value of $41 200)
180 Life Sciences Corp.
180 Life Sciences Corp is a clinical-stage biotechnology company. It is focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics.
CEO: James N. Woody
Telephone: +1 302 502-2727
Address: 830 Menlo Avenue, Menlo Park 94025, CA, US
Number of employees: 0
